bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?

bioMerieux (OTCMKTS:BMXMF) shares gapped up before the market opened on Tuesday . The stock had previously closed at $83.17, but opened at $88.4950. bioMerieux shares last traded at $88.4950, with a volume of 106 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Zacks Research downgraded shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Piper Sandler initiated coverage on shares of bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Finally, Morgan Stanley cut bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, bioMerieux presently has a consensus rating of “Reduce”.

bioMerieux Stock Performance

The company has a 50-day moving average of $80.29 and a two-hundred day moving average of $92.83. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.